Grace Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Prashant Kohli
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 103 Carnegie Center Princeton NJ United States of America 08540
- IPO Date
- Feb 7, 2012
- CIK
- 0001444192
- Website
- gracetx.com
- Similar Companies
- Business
- Grace Therapeutics, Inc. (Nasdaq: GRCE) is a late-stage biopharmaceutical company focused on developing and commercializing novel drug delivery technologies and pharmaceutical products for rare and orphan diseases, including aneurysmal subarachnoid hemorrhage, ataxia-telangiectasia, and postherpetic neuralgia. Founded in 2002 and headquartered in Princeton, New Jersey, the company offers a pipeline of clinical-stage assets comprising GTx-104, an intravenous infusion formulation of nimodipine targeting aneurysmal subarachnoid hemorrhage; GTx-102, an oral mucosal spray of betamethasone to improve neurological symptoms in ataxia-telangiectasia; and GTx-101, a topical bioadhesive film-forming bupivacaine spray for pain associated with postherpetic neuralgia; each granted Orphan Drug Designation by the U.S. FDA, providing seven years of marketing exclusivity post-approval and supported by over 40 granted and pending patents worldwide. Grace Therapeutics operates primarily in the United States with a focus on neurological disorders underserved by current therapies. In October 2024, the company changed its name from Acasti Pharma Inc. to better reflect its scientific advancements and mission; recently secured up to $30 million in private placement financing led by Nantahala Capital and ADAR1 Partners, LP in February 2025 to support pre-commercial development of GTx-104, followed by $4 million from warrant exercises in October 2025 and a Type C meeting with the FDA on its planned New Drug Application submission as announced in its 2025 fiscal year-end results.
Company News
Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
Grace Therapeutics Announces $10 Million Private Placement
Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
Grace Therapeutics (NASDAQ:GRCE) Trading Down 2.5% – Here’s What Happened
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
GRCE INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Grace Therapeutics, Inc.
Grace Therapeutics: Assessing The Path Forward For GTx-104
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE
Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug
US FDA declines to approve Grace Therapeutics' drug for a type of stroke
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026